TP53 and pancreatic neoplasm: Specifically, they recently demonstrated that only in pancreatic cancer PDXs with mutant TP53, which is characterized by a higher glucose uptake compared to wild-type TP53 tumors, FX11 was able to inhibit the pyruvate-to-lactate conversion.